View Financial HealthStella Diagnostics 配当と自社株買い配当金 基準チェック /06Stella Diagnostics配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jan 06ProPhase Labs, Inc. (NasdaqCM:PRPH) acquired World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for $4.6 million.ProPhase Labs, Inc. (NasdaqCM:PRPH) entered into an asset purchase agreement to acquire World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for $4.5 million on December 19, 2022. As consideration for the Purchased Assets, ProPhase Labs, Inc. will (i) pay to the Stella Diagnostics Inc. $3.486 million in cash, minus (a) the Secured Note Amount, if any, (b) the Liability Payoff Amount and (c) the Promissory Note Payoff Amounts and (ii) issue to Stella DX 0.1 million shares of common stock, par value $0.0005 per share, of ProPhase Labs, Inc. Under the terms of the agreement, an additional $2 million of ProPhase Labs common stock may be issued to Stella in the future upon the achievement of a revenue-based commercial milestone within the five-year period following the closing. The transaction is subject to customary closing conditions, including the receipt of all required approvals, consents and waivers, including the requisite approval by the stockholders of Stella and is expected to close in early January 2023. ThinkEquity acted as advisor to ProPhase Labs in the transaction. Reed Smith LLP acted as legal advisor to ProPhase Labs. Thompson Hine LLP acted as legal advisor to Stella Diagnostics in the transaction. ProPhase Labs, Inc. (NasdaqCM:PRPH) acquired World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for $4.6 million on January 5, 2023.お知らせ • Dec 21ProPhase Labs, Inc. (NasdaqCM:PRPH) entered into an asset purchase agreement to acquire World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for approximately $4.5 million.ProPhase Labs, Inc. (NasdaqCM:PRPH) entered into an asset purchase agreement to acquire World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for approximately $4.5 million on December 19, 2022. The purchase price comprised of approximately $3.5 million in cash and $1 million in ProPhase common stock. Under the terms of the agreement, an additional $2 million of Company common stock may be issued to Stella in the future upon the achievement of a revenue-based commercial milestone within the five-year period following the closing. The transaction is subject to approval by Stella shareholders and is expected to close in early January 2023. ThinkEquity acted as advisor to ProPhase Labs in the transaction.お知らせ • Apr 23+ 1 more updateStella Diagnostics Inc. Appointment of Joe Abdo as Chief Scientific OfficerStella Diagnostics Inc. announced leadership changes in conjunction with the next phase of its business plan. In order to successfully implement new processes, products, and business strategies, Dr. Joe Abdo will assume the newly created position of Chief Scientific Officer, and David Seaburg, who is currently a member of Stella Diagnostics’ Board of Directors, has been appointed Chief Executive Officer. The planned leadership transition reflects Stella Diagnostics’ Board of Directors succession planning process. Accordingly, the Board conducted a comprehensive evaluation of internal and external candidates. Following a thorough assessment, the Board unanimously determined the leadership changes. Dr. Joe Abdo has over a decade of experience in molecular oncology research, as well as business development in both private and public biotechnology organizations. Dr. Joe Abdo has over a decade of experience in molecular oncology research, as well as business development in both private and public biotechnology organizations.お知らせ • Sep 03JMD Properties Inc. (OTCPK:JMDP) acquired Stella Diagnostics, LLC.JMD Properties Inc. (OTCPK:JMDP) acquired Stella Diagnostics, LLC on September 2, 2020. The transaction was a preferred stock acquisition. JMD Properties will be changing its name to Stella Diagnostics, Inc. In conjunction with the acquisition and name change, the company will be filing for a symbol change. The company will be filing this corporate action with FINRA. JMD Properties Inc. (OTCPK:JMDP) completed the acquisition of Stella Diagnostics, LLC on September 2, 2020.決済の安定と成長配当データの取得安定した配当: SLDXの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: SLDXの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Stella Diagnostics 配当利回り対市場SLDX 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (SLDX)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Healthcare)1.9%アナリスト予想 (SLDX) (最長3年)n/a注目すべき配当: SLDXは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: SLDXは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: SLDXの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: SLDXが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 22:34終値2026/06/10 00:00収益2013/12/31年間収益2013/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Stella Diagnostics, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 06ProPhase Labs, Inc. (NasdaqCM:PRPH) acquired World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for $4.6 million.ProPhase Labs, Inc. (NasdaqCM:PRPH) entered into an asset purchase agreement to acquire World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for $4.5 million on December 19, 2022. As consideration for the Purchased Assets, ProPhase Labs, Inc. will (i) pay to the Stella Diagnostics Inc. $3.486 million in cash, minus (a) the Secured Note Amount, if any, (b) the Liability Payoff Amount and (c) the Promissory Note Payoff Amounts and (ii) issue to Stella DX 0.1 million shares of common stock, par value $0.0005 per share, of ProPhase Labs, Inc. Under the terms of the agreement, an additional $2 million of ProPhase Labs common stock may be issued to Stella in the future upon the achievement of a revenue-based commercial milestone within the five-year period following the closing. The transaction is subject to customary closing conditions, including the receipt of all required approvals, consents and waivers, including the requisite approval by the stockholders of Stella and is expected to close in early January 2023. ThinkEquity acted as advisor to ProPhase Labs in the transaction. Reed Smith LLP acted as legal advisor to ProPhase Labs. Thompson Hine LLP acted as legal advisor to Stella Diagnostics in the transaction. ProPhase Labs, Inc. (NasdaqCM:PRPH) acquired World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for $4.6 million on January 5, 2023.
お知らせ • Dec 21ProPhase Labs, Inc. (NasdaqCM:PRPH) entered into an asset purchase agreement to acquire World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for approximately $4.5 million.ProPhase Labs, Inc. (NasdaqCM:PRPH) entered into an asset purchase agreement to acquire World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for approximately $4.5 million on December 19, 2022. The purchase price comprised of approximately $3.5 million in cash and $1 million in ProPhase common stock. Under the terms of the agreement, an additional $2 million of Company common stock may be issued to Stella in the future upon the achievement of a revenue-based commercial milestone within the five-year period following the closing. The transaction is subject to approval by Stella shareholders and is expected to close in early January 2023. ThinkEquity acted as advisor to ProPhase Labs in the transaction.
お知らせ • Apr 23+ 1 more updateStella Diagnostics Inc. Appointment of Joe Abdo as Chief Scientific OfficerStella Diagnostics Inc. announced leadership changes in conjunction with the next phase of its business plan. In order to successfully implement new processes, products, and business strategies, Dr. Joe Abdo will assume the newly created position of Chief Scientific Officer, and David Seaburg, who is currently a member of Stella Diagnostics’ Board of Directors, has been appointed Chief Executive Officer. The planned leadership transition reflects Stella Diagnostics’ Board of Directors succession planning process. Accordingly, the Board conducted a comprehensive evaluation of internal and external candidates. Following a thorough assessment, the Board unanimously determined the leadership changes. Dr. Joe Abdo has over a decade of experience in molecular oncology research, as well as business development in both private and public biotechnology organizations. Dr. Joe Abdo has over a decade of experience in molecular oncology research, as well as business development in both private and public biotechnology organizations.
お知らせ • Sep 03JMD Properties Inc. (OTCPK:JMDP) acquired Stella Diagnostics, LLC.JMD Properties Inc. (OTCPK:JMDP) acquired Stella Diagnostics, LLC on September 2, 2020. The transaction was a preferred stock acquisition. JMD Properties will be changing its name to Stella Diagnostics, Inc. In conjunction with the acquisition and name change, the company will be filing for a symbol change. The company will be filing this corporate action with FINRA. JMD Properties Inc. (OTCPK:JMDP) completed the acquisition of Stella Diagnostics, LLC on September 2, 2020.